Posted by Michael Wonder on 24 Mar 2019
As political scrutiny mounts, Eli Lilly divulges new insulin pricing data
24 March 2019 - Lilly says the price it was paid for popular insulin Humalog fell 8.1% from 2014 to 2018 due to increasing rebates it gave to companies in the drug-supply chain.
Eli Lilly & Co., facing mounting scrutiny in the U.S. Congress over big increases in the list price of a widely used insulin, says the price it was paid dropped by 8.1% during the previous five years after accounting for rebates and discounts.
Lilly says the net price for its Humalog insulin—the price after discounts and rebates—fell to an average of $135 a patient a month in 2018, from $147 in 2014. During the same period, the product’s average list price rose 51.9% to $594 per patient monthly.
